← Back to Clinical Trials
Recruiting NCT04290806

NCT04290806 Registry Platform Gastric/Esophageal Cancer (SAPHIR)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04290806
Status Recruiting
Phase
Sponsor iOMEDICO AG
Condition Esophageal Squamous Cell Carcinoma
Study Type OBSERVATIONAL
Enrollment 1,900 participants
Start Date 2019-12-04
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Routine care as per site standard

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,900 participants in total. It began in 2019-12-04 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.

Eligibility Criteria

Inclusion Criteria: * Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC * Planned palliative systemic first-line therapy * Age \>= 18 years * Signed informed consent (IC) * Patients answering questionnaires: IC before first therapy cycle * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle Exclusion Criteria: * No systemic therapy for ESCC, EAC, GAC or GEJAC

Contact & Investigator

Central Contact

Adrian Binninger

✉ info@iomedico.com

📞 +49 761 152 42 - 0

Principal Investigator

Tobias Dechow, Prof.

STUDY CHAIR

Ravensburg

Frequently Asked Questions

Who can join the NCT04290806 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04290806 currently recruiting?

Yes, NCT04290806 is actively recruiting participants. Contact the research team at info@iomedico.com for enrollment information.

Where is the NCT04290806 trial being conducted?

This trial is being conducted at Multiple Locations, Germany.

Who is sponsoring the NCT04290806 clinical trial?

NCT04290806 is sponsored by iOMEDICO AG. The principal investigator is Tobias Dechow, Prof. at Ravensburg. The trial plans to enroll 1,900 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology